Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
PIP's Cash to Debt is ranked higher than
96% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 59.90 vs. PIP: No Debt )
Ranked among companies with meaningful Cash to Debt only.
PIP' s Cash to Debt Range Over the Past 10 Years
Min: 0.03  Med: 7.25 Max: No Debt
Current: No Debt
Equity to Asset 0.97
PIP's Equity to Asset is ranked higher than
97% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. PIP: 0.97 )
Ranked among companies with meaningful Equity to Asset only.
PIP' s Equity to Asset Range Over the Past 10 Years
Min: -0.53  Med: 0.57 Max: 0.97
Current: 0.97
-0.53
0.97
F-Score: 6
Z-Score: 13.14
M-Score: -6.33
WACC vs ROIC
23.70%
-784.97%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -124.43
PIP's Operating margin (%) is ranked lower than
55% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -88.13 vs. PIP: -124.43 )
Ranked among companies with meaningful Operating margin (%) only.
PIP' s Operating margin (%) Range Over the Past 10 Years
Min: -873.96  Med: -97.15 Max: -24.89
Current: -124.43
-873.96
-24.89
Net-margin (%) 2134.88
PIP's Net-margin (%) is ranked higher than
99% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. PIP: 2134.88 )
Ranked among companies with meaningful Net-margin (%) only.
PIP' s Net-margin (%) Range Over the Past 10 Years
Min: -909.98  Med: -95.24 Max: 2134.88
Current: 2134.88
-909.98
2134.88
ROE (%) 272.61
PIP's ROE (%) is ranked higher than
100% of the 874 Companies
in the Global Biotechnology industry.

( Industry Median: -34.32 vs. PIP: 272.61 )
Ranked among companies with meaningful ROE (%) only.
PIP' s ROE (%) Range Over the Past 10 Years
Min: -453.67  Med: -76.43 Max: 272.61
Current: 272.61
-453.67
272.61
ROA (%) 251.83
PIP's ROA (%) is ranked higher than
100% of the 972 Companies
in the Global Biotechnology industry.

( Industry Median: -30.23 vs. PIP: 251.83 )
Ranked among companies with meaningful ROA (%) only.
PIP' s ROA (%) Range Over the Past 10 Years
Min: -111.46  Med: -43.29 Max: 251.83
Current: 251.83
-111.46
251.83
ROC (Joel Greenblatt) (%) -3293.31
PIP's ROC (Joel Greenblatt) (%) is ranked lower than
76% of the 925 Companies
in the Global Biotechnology industry.

( Industry Median: -407.53 vs. PIP: -3293.31 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
PIP' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -3293.31  Med: -281.39 Max: -39.54
Current: -3293.31
-3293.31
-39.54
Revenue Growth (3Y)(%) -31.70
PIP's Revenue Growth (3Y)(%) is ranked lower than
79% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. PIP: -31.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
PIP' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -31.7  Med: -27.1 Max: 173.6
Current: -31.7
-31.7
173.6
EBITDA Growth (3Y)(%) -25.40
PIP's EBITDA Growth (3Y)(%) is ranked lower than
78% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. PIP: -25.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
PIP' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -66.7  Med: -33.7 Max: 36.4
Current: -25.4
-66.7
36.4
EPS Growth (3Y)(%) -20.60
PIP's EPS Growth (3Y)(%) is ranked lower than
69% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: -3.10 vs. PIP: -20.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
PIP' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -68.7  Med: -40.3 Max: 28.6
Current: -20.6
-68.7
28.6
GuruFocus has detected 2 Warning Signs with PharmAthene Inc $PIP.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» PIP's 10-Y Financials

Financials (Next Earnings Date: 2017-03-10)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

PIP Guru Trades in

Q2 2016

PIP Guru Trades in Q2 2016

Jim Simons 149,200 sh (New)
» More
Q3 2016

PIP Guru Trades in Q3 2016

Jim Simons 514,335 sh (+244.73%)
» More
Q4 2016

PIP Guru Trades in Q4 2016

Jim Simons 3,347,141 sh (+550.77%)
» More
» Details

Insider Trades

Latest Guru Trades with PIP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:AMEX:NAVB, NAS:BLRX, NAS:IPCI, NAS:AGLE, NAS:KALV, NAS:GTXI, OTCPK:IMMG, NAS:PULM, NAS:BUR, NAS:BCLI, NAS:CBAY, OTCPK:CWBR, NAS:CAPR, OTCPK:TBQBF, OTCPK:CNNRF, NAS:SBPH, NAS:ALDX, NAS:ADMA, NAS:TTNP, NAS:TCON » details
Traded in other countries:3G0.Germany,
PharmAthene Inc is a biodefense company. It is engaged in the development and commercialization of medical countermeasures against biological and chemical weapons in the United States.

PharmAthene Inc was incorporated under the laws of the State of Delaware on April 25, 2005. It is a biodefense company, which is engaged in the development and commercialization of medical countermeasures against biological and chemical weapons. Its biodefense portfolio includes the product candidates namely SparVax, a second generation recombinant protective antigen (rPA) anthrax vaccine; Valortim, a fully human monoclonal antibody for the prevention and treatment of anthrax infection, and; rBChE (recombinant butyrylcholinesterase) bioscavanger, a medical countermeasure for nerve agent poisoning by organophosphorous compounds, including nerve gases and pesticides. The Company's customers are the U.S. Department of Defense (the DoD), the National Institute of Allergy and Infectious Diseases ('NIAID), and the National Institute of Health (NIH). Its competitors include Emergent BioSolutions, Inc., Green Cross, Panacea Biotec Ltd., and PaxVax, among others. The Company is subject to various federal, state and local laws, regulations and recommendations relating to safe working conditions, laboratory and manufacturing practices, the experimental use of animals, and the use and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with its various activities.

Ratios

vs
industry
vs
history
P/E(ttm) 0.59
PIP's P/E(ttm) is ranked higher than
97% of the 277 Companies
in the Global Biotechnology industry.

( Industry Median: 27.60 vs. PIP: 0.59 )
Ranked among companies with meaningful P/E(ttm) only.
PIP' s P/E(ttm) Range Over the Past 10 Years
Min: 0.59  Med: 13.48 Max: 166
Current: 0.59
0.59
166
PE(NRI) 0.59
PIP's PE(NRI) is ranked higher than
97% of the 251 Companies
in the Global Biotechnology industry.

( Industry Median: 27.87 vs. PIP: 0.59 )
Ranked among companies with meaningful PE(NRI) only.
PIP' s PE(NRI) Range Over the Past 10 Years
Min: 0.59  Med: 13.74 Max: 138.33
Current: 0.59
0.59
138.33
Price/Owner Earnings (ttm) 0.60
PIP's Price/Owner Earnings (ttm) is ranked higher than
99% of the 143 Companies
in the Global Biotechnology industry.

( Industry Median: 29.18 vs. PIP: 0.60 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
PIP' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 0.6  Med: 1.87 Max: 53.96
Current: 0.6
0.6
53.96
P/B 0.51
PIP's P/B is ranked higher than
97% of the 1106 Companies
in the Global Biotechnology industry.

( Industry Median: 3.65 vs. PIP: 0.51 )
Ranked among companies with meaningful P/B only.
PIP' s P/B Range Over the Past 10 Years
Min: 0.51  Med: 5.6 Max: 31.07
Current: 0.51
0.51
31.07
P/S 12.53
PIP's P/S is ranked higher than
50% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: 12.50 vs. PIP: 12.53 )
Ranked among companies with meaningful P/S only.
PIP' s P/S Range Over the Past 10 Years
Min: 0.41  Med: 3.52 Max: 82.18
Current: 12.53
0.41
82.18
PFCF 0.59
PIP's PFCF is ranked higher than
99% of the 140 Companies
in the Global Biotechnology industry.

( Industry Median: 22.44 vs. PIP: 0.59 )
Ranked among companies with meaningful PFCF only.
PIP' s PFCF Range Over the Past 10 Years
Min: 0.59  Med: 42.17 Max: 72.17
Current: 0.59
0.59
72.17
POCF 0.59
PIP's POCF is ranked higher than
99% of the 204 Companies
in the Global Biotechnology industry.

( Industry Median: 21.56 vs. PIP: 0.59 )
Ranked among companies with meaningful POCF only.
PIP' s POCF Range Over the Past 10 Years
Min: 0.59  Med: 42.17 Max: 72.17
Current: 0.59
0.59
72.17
Current Ratio 37.03
PIP's Current Ratio is ranked higher than
98% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. PIP: 37.03 )
Ranked among companies with meaningful Current Ratio only.
PIP' s Current Ratio Range Over the Past 10 Years
Min: 0.41  Med: 3.87 Max: 389.51
Current: 37.03
0.41
389.51
Quick Ratio 37.03
PIP's Quick Ratio is ranked higher than
98% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: 3.91 vs. PIP: 37.03 )
Ranked among companies with meaningful Quick Ratio only.
PIP' s Quick Ratio Range Over the Past 10 Years
Min: 0.41  Med: 3.87 Max: 389.51
Current: 37.03
0.41
389.51
Days Sales Outstanding 45.20
PIP's Days Sales Outstanding is ranked higher than
64% of the 592 Companies
in the Global Biotechnology industry.

( Industry Median: 62.87 vs. PIP: 45.20 )
Ranked among companies with meaningful Days Sales Outstanding only.
PIP' s Days Sales Outstanding Range Over the Past 10 Years
Min: 3.98  Med: 54.35 Max: 319.57
Current: 45.2
3.98
319.57

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -10.00
PIP's 3-Year Average Share Buyback Ratio is ranked higher than
53% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. PIP: -10.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PIP' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -34.2  Med: -21.45 Max: -4.2
Current: -10
-34.2
-4.2

Valuation & Return

vs
industry
vs
history
Price/Net Cash 0.52
PIP's Price/Net Cash is ranked higher than
99% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: 5.89 vs. PIP: 0.52 )
Ranked among companies with meaningful Price/Net Cash only.
PIP' s Price/Net Cash Range Over the Past 10 Years
Min: 0.52  Med: 12.93 Max: 186
Current: 0.52
0.52
186
Price/Net Current Asset Value 0.52
PIP's Price/Net Current Asset Value is ranked higher than
99% of the 879 Companies
in the Global Biotechnology industry.

( Industry Median: 5.57 vs. PIP: 0.52 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
PIP' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.52  Med: 7.18 Max: 73.33
Current: 0.52
0.52
73.33
Price/Tangible Book 0.52
PIP's Price/Tangible Book is ranked higher than
98% of the 1015 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. PIP: 0.52 )
Ranked among companies with meaningful Price/Tangible Book only.
PIP' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.52  Med: 6.48 Max: 36.02
Current: 0.52
0.52
36.02
Price/Projected FCF 0.28
PIP's Price/Projected FCF is ranked higher than
97% of the 174 Companies
in the Global Biotechnology industry.

( Industry Median: 3.31 vs. PIP: 0.28 )
Ranked among companies with meaningful Price/Projected FCF only.
PIP' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.28  Med: 0.79 Max: 0.79
Current: 0.28
0.28
0.79
Price/Median PS Value 3.59
PIP's Price/Median PS Value is ranked lower than
91% of the 765 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. PIP: 3.59 )
Ranked among companies with meaningful Price/Median PS Value only.
PIP' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.19  Med: 0.94 Max: 23.43
Current: 3.59
0.19
23.43
Price/Graham Number 0.12
PIP's Price/Graham Number is ranked higher than
98% of the 229 Companies
in the Global Biotechnology industry.

( Industry Median: 2.38 vs. PIP: 0.12 )
Ranked among companies with meaningful Price/Graham Number only.
PIP' s Price/Graham Number Range Over the Past 10 Years
Min: 0.12  Med: 2.11 Max: 3.59
Current: 0.12
0.12
3.59
Earnings Yield (Greenblatt) (%) -6.90
PIP's Earnings Yield (Greenblatt) (%) is ranked higher than
55% of the 1203 Companies
in the Global Biotechnology industry.

( Industry Median: -9.03 vs. PIP: -6.90 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
PIP' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -6.9  Med: 1.3 Max: 2239
Current: -6.9
-6.9
2239

More Statistics

Revenue (TTM) (Mil) $5.38
EPS (TTM) $ 1.75
Beta2.84
Short Percentage of Float1.50%
52-Week Range $0.47 - 3.50
Shares Outstanding (Mil)68.82
» More Articles for PIP

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: BWEN, ENZ, PIP, HAFC, AACC Nov 21 2011 
PharmAthene Inc (PIP) CEO Eric I Richman buys 10,000 Shares Jun 21 2010 
Guru Activities for Today’s Price % Losers: PharmAthene Inc. , Authentidate Holding Corp., Kroger Dec 08 2009 

More From Other Websites
Pepsico CFO: Great business in Mexico Feb 15 2017
Pepsico CFO: We have terrific momentum Feb 15 2017
Biotech Premarket Movers: PharmAthene, Earth Science Tech, Pulmatrix Feb 07 2017
Rite Aid, Supervalu Slump into Monday’s 52-Week Low Club Feb 06 2017
Altimmune to Present at the BIO CEO & Investor Conference Feb 06 2017
PHARMATHENE, INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Feb 01 2017
[$$] Gormley's Take: As IPO Market Tightens, Biotechs Find Another Route to Public Listing Feb 01 2017
PharmAthene and Altimmune to Merge in All-Stock Deal Jan 23 2017
ETFs with exposure to PharmAthene, Inc. : January 20, 2017 Jan 20 2017
Blog Coverage PharmAthene and Altimmune Announced a Merger; Set to Establish Immunotherapeutic... Jan 20 2017
Two of region's anthrax-fighting companies announce merger Jan 20 2017
PHARMATHENE, INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors... Jan 19 2017
PharmAthene and Altimmune Announce Merger to Create Immunotherapeutics Company Targeting Infectious... Jan 19 2017
ETFs with exposure to PharmAthene, Inc. : January 9, 2017 Jan 09 2017
ETFs with exposure to PharmAthene, Inc. : December 29, 2016 Dec 29 2016
ETFs with exposure to PharmAthene, Inc. : December 16, 2016 Dec 16 2016
ETFs with exposure to PharmAthene, Inc. : December 5, 2016 Dec 05 2016
PharmAthene Declares $2.91 Special Cash Dividend on Common Stock Nov 17 2016
PharmAthene Receives Final Payment from SIGA of $83.9 Million Nov 16 2016
PHARMATHENE, INC Financials Nov 10 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)